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ABSTRACT
Background: Chronic rhinosinusitis (CRS) is classified in CRS without nasal polyp (CRSsNP) and CRS with
nasal polyp (CRSwNP) in western countries, whereas this classification was not common so far in Japan.
Studying inflammatory mediators in clearly defined disease subgroups may lead to a better differentiation of
chronic sinus diseases.
Methods: Homogenates of sinonasal mucosal tissue from 14 controls, 9 CRSsNP patients, and 19 CRSwNP
patients were assayed for transforming growth factor (TGF)-β, interleukin (IL)-5, immunoglobulin E (IgE),
Staphylococcus enterotoxin (SAE)-IgE, eosinophil-catioic protein (ECP), myeloperoxidase (MPO), IL-1β, IL-6,
and IL-8 by enzyme-linked immunosorbent assay or UNICAP system.
Results: CRSwNP had significantly higher levels of IL-5, IgE, SAE-IgE, and ECP compared with CRSsNP and
controls. CRSsNP was characterized by high levels of TGF-β, while CRSwNP showed a Th2 polarization and
lower levels of TGF-β. Especially, in CRSwNP samples, 68.4% were eosinophilic (ECPMPO ratio >1), and
52.6% were SAE-IgE positive. On the other hand, in 9 CRSsNP patients, eosinophilic or SAE-IgE positive sam-
ple was only one sample respectively. Additionally, 31.6% of CRSwNP were asthmatic patients, while none of
CRSsNP patient was suffering from bronchial asthma.
Conclusions: This study is thought to be the first one that showed the cytokine profiles in Japanese CRSs
wNP similar to those of European CRS. Based on mediator profiles, we suggest that CRSsNP and CRSwNP
are distinct disease entities within the group of chronic sinus diseases.
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INTRODUCTION
Chronic rhinosinusitis (CRS) is one of the most com-
mon diseases in the otolaryngology area. In western
countries including Europe and America, the nasal
polyp is considered to be the result of eosinophilic in-
flammation in nasal mucosa, and it is generally ac-
cepted that CRS is classified in CRS without nasal
polyp (CRSsNP) and CRS with nasal polyp
(CRSwNP). Recent research has demonstrated that
the pathologies of CRSsNP and CRSwNP can be dif-
ferentiated into distinct subgroups on the basis of the
expression of inflammatory mediators1 and histopa-
thology.2,3 On the other hand, in former Japan, CRS
caused by bacterial infection held an overwhelming
majority, and the main inflammatory cell which infil-
trated in tissues including nasal polyps was the neu-
trophil.4 The CRS classification such as CRSsNP or
CRSwNP was not common so far in Japan. At present,
however, characteristics of nasal polyp in Japan re-
semble those in Europe and America, and eosino-
philic infiltration is a more common feature histologi-
cally.4 Such classification based on the pathophysiol-
ogy of the disease may be useful for the decision for
the treatment.
CRS is characterized by chronic inflammation of
the nasal and paranasal mucosa, accompanied by tis-
sue remodeling that includes changes in the extracel-
lular matrix (ECM) protein deposition and tissue
structure.2 In western countries, CRSsNP is charac-
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Table　1　Patient characteristics and symptom scores
Controls 
subjects
CRSsNP 
patients
CRSwNP 
patients
ANOVA
 (Fisher†)
No. 14 9 19
Age (years; range) 62.5 (21-80) 57 (29-71) 56 (17-71)
Female/male sex 4/10 4/5 4/15 0.216
Atopic status 0/14 2/9 7/19 0.011†
Asthma 0/14 0/9 6/19 0.020†
CT score 0 (0-1) 5 (2-10) 16 (10-20) <0.001
Total symptom score 4 (3-5) 6 (2-10) 10 (4-14) <0.001
Nasal congestion 1 (1-2) 1 (0-2) 3 (2-3) <0.001
Sneezing  0 1 (0-1) 1 (0-2) 0.520
Rhinorrhea 0 (0-1) 1 (0-3) 1 (0-3) 0.066
Loss of smell  0 0 (0-1) 2 (0-3) <0.001
Postnasal drip  0 1 (0-2) 1 (0-3) 0.020
Headache 0 (0-1) 2 (1-3) 1 (0-3) 0.001
The total symptom scores is the sum of the score for nasal congestion, rhinorrhee, headache, postnasal drip, loss of smell, and sneezing. 
The level of signifi cance (P) was obtained by means of ANOVA or the Fisher exact test (marked with †); comparison between CRSsNP
and CRSwNP. The CT score was obtained using the Lund-Mackay classifi cation. The polyp size was scored according to the Davos classi-
fi cation.
terized by high levels of transforming growth factor
(TGF)-β.2,3,5 In contrast, CRSwNP is characterized by
a predominant Th2-biased eosinophilic inflammation
with high levels of IL-5, and eosinophilic cationic pro-
tein (ECP); high levels of local IgE; and low levels of
TGF-β.2,5,6 However, recent studies in China revealed
a different inflammatory cytokine pattern with a more
neutrophilic, IL-17 driven type, although remodeling
pattern were similar to European patients.7,8 In the
current study, we investigated the cytokine and me-
diator pattern in different subgroups of Japanese pa-
tients with CRS: CRSsNP, CRSwNP, and controls (no
allergic and sinus disease). Based on previous stud-
ies in CRS with and without NP, the following groups
of mediators were carefully selected: proinflamma-
tory cytokines (IL-1β, IL-6), eosinophil-related media-
tors (ECP), neutrophil-related mediators [IL-8,
myeloperoxidase (MPO)], T cell and subset markers
[interferon (IFN)-γ, IL-5, IL-17], a T-regulatory
marker (TGF-β), and IgE [total IgE, Staphylococcus
enterotoxin (SAE)-IgE]. The aim of this study was to
possibly identify differences in the profile of inflam-
matory mediators and cellular characteristics for
each of the selected disease subgroups in Japan.
METHODS
PATIENTS
Sinonasal mucosa from Japanese patients with
CRSsNP (n = 9), CRSwNP (n = 19) and control pa-
tients (CTR; n = 14) was obtained at the Department
of Otorhinolaryngology-Head and Neck Surgery of
the Jichi Medical University Hospital, Japan. Inferior
turbinates from patients without sinus disease under-
going septoplasty or rhinoseptoplasty were collected
as controls based on the previous report.9 For
CRSsNP and CRSwNP, tissue samples originated
from ethmoidal mucosa during routine endonasal si-
nus surgery in consecutive patients scheduled for
surgery unrelated to the study. The diagnosis of si-
nus disease was based on history, clinical examina-
tion, nasal endoscopy, and computed tomography
(CT)-scan of the paranasal cavities according to the
European Position Paper on Rhinosinusitis and Nasal
Polyps guidelines.10 CT scans were graded according
to the Lund-MacKay method.11 Individual rhinosi-
nusitis symptoms were evaluated by a physician on a
scale of 0 to 3 (no symptoms, mild symptoms, moder-
ate symptoms, and severe symptoms) before surgery,
according to the Davos classification.10 The reasons
for surgical procedures were unrelated to the study
in all patients. The atopic status was evaluated by us-
ing the ImmunoCAPⓇ test (Phadia, Uppsala, Swe-
den), detecting specific IgE antibodies against House
dust mite (Dermatophagoides pteronyssinus), Japanese
cedar (Cryptomeria japonica), Orchard grass (Dac-
tylis glomerata), Common ragweed (Ambrosia elatior)
or Cat dander (Felis domesticus). The patient who
showed more than class 2 for at least one of these al-
lergens was defined as an atopic patient. The diagno-
sis of asthma and aspirin sensitivity was performed
by a pneumologist based on lung function and chal-
lenge tests, where applicable. All patients stopped
oral and topical application of corticosteroids for at
least 1 month before surgery. Patients did not take
any other relevant medication. An informed consent
was obtained from each patient and control subject
before collecting material, and the study was ap-
proved by the local ethical committee of the Jichi
Medical University Hospital.
Cytokines in Chronic Rhinosinusitis
Allergology International Vol 61, No1, 2012 www.jsaweb.jp 117
Fig.　1　Pathological fi ndings in mucosa. The sections were stained with hematoxylin-eosin in controls (A 
and B), CRSsNP (C and D), and CRSwNP (E and F), respectively. Arrows indicate eosinophils. Asterisks 
indicate pseudocyst formation. Bars; 20 μm.
Control CRSsNP CRSwNP
HISTOPATHOLOGIC ANALYSIS
The tissue was fixed with 10% neutral buffered forma-
lin solution for 1 week, embedded in paraffin, and cut
into 2-μm-thick sections. After hematoxylin-eosin
(HE) staining, histopathologic analysis was per-
formed by selecting a representative field of mucosa
where the most prominent change was detected with
×200 magnification. The number of eosinophils was
analyzed by using a magnification ×200. 5 fields of the
mucosal area were evaluated at random, and the
number of eosinophilsfield was counted for each
sample by two independent evaluators.
MEASUREMENT OF CYTOKINE AND IgE LEV-
ELS
Freshly obtained tissue specimens were homoge-
nized in Japan as previously described.12 For homog-
enization, the tissue was thawed, weighed and 1 mL
saline was added per every 0.1 g tissue. The tissue
was then homogenized at 1000 rpm for 3 min on ice
(homogeniser; B.Braun, Melsungen, Germany). The
homogenates were centrifuged at 3000 rpm for 10
min at 4℃. After centrifugation, supernatants were
aliquot in 500 μL and stored at -80℃ until analysis. All
samples were assayed for IL-1β, IL-5, IL-6, IL-8, IL-10,
IL-17, IFN-γ, TGF-β and MPO by using commercially
available ELISA kits (Quantikine ELISA, R&D Sys-
tems, Minneapolis, MN, USA; MPO, Oxis Interna-
tional, Portland, OR, USA). ECP, IgE and SAE-IgE
(IgE to Staphylococcus enterotoxin A, C, and TSST-
1; 0.35-100 kUAL) were measured by using the
UNICAP system (Pharmacia, Uppsala, Sweden).
These assays were performed in Belgium following
the manufacturer’s instructions. An ECPMPO ratio
was calculated as described before.7 Standard curves
and controls were performed according to the guide-
lines of the producer.
STATISTICAL ANALYSIS
Statistical analysis was performed with SPSS Statis-
tics software v 17.0 (SPSS, Chicago, IL, USA). Data
are expressed as median, range and interquartiles.
Statistical analysis was performed by using the
Kruskal-Wallis test and the Mann-Whitney U 2-tailed
test for unpaired comparisons. When comparisons
were made between groups, the Kruskal-Wallis test
was used to establish the significant intergroup vari-
ability. The Mann-Whitney U test with with Bonfer-
roni correction was then used for between-group
comparisons. Baseline variables were analyzed by us-
ing a 1-way ANOVA test or the Fisher exact test. A
statistical difference of P < 0.05 was considered sig-
nificant.
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Fig.　2　Measurement of transforming growth factor (TGF)-β, interleukin (IL)-5, immunoglobulin E 
(IgE), Staphylococcus enterotoxin (SAE)-IgE, eosinophil-related mediators (ECP), myeloperoxidase 
(MPO), IL-1β, IL-6, and IL-8 by enzyme-linked immunosorbent assay in 14 controls (CTR), 9 chronic 
rhinosinusitis without nasal polyp patients (CRSsNP), and 19 chronic rhinosinusitis with nasal polyp 
patients (CRSwNP). Values are reported as medians and interquartile ranges for each group. Statisti-
cal analysis was performed using the Kruskal-Wallis test followed by a Mann-Whitney U-test with 
Bonferroni correction. The signifi cance level was set at a P value of 0.05. From these data, an ECP/
MPO ratio was calculated. *P < 0.05; **P < 0.01.
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Table　2　Cytokine concentrations in CRSwNP subgroups with and without atopic status
CRSwNP with atopic status (n = 7) CRSwNP without atopic status (n = 12) P value
ECP (μg/L) 27600 (3660-58500) 5750 (2960-13100) 0.033*
MPO (ng/mL) 8875 (273-24683) 3703 (637-11558) 0.914
IL-5 (pg/mL) 511 (54-720) 26 (6-37) 0.009**
IFN-γ (pg/mL) 78 (78-78) 156 (78-1016) 0.298
IgE (KU/L) 1070 (540-1265) 354 (55-477) 0.009**
SAE-IgE (KU/L) 8.2 (5.2-14.3) 0 (0-3.8) 0.004**
IL-1β (pg/mL) 37 (23-1097) 34 (27-410) 0.762
IL-6 (pg/mL) 351 (303-1109) 95 (47-461) 0.258
IL-8 (pg/mL) 5345 (2213-25243) 8693 (1550-25708) 0.904
IL-17 (pg/mL) 11 (11-11) 11 (11-149) 0.285
TGF-β (pg/mL) 13837 (11635-18809) 13689 (9374-15239) 0.610
Data are expressed as medians and interquartile ranges. *P < 0.05 and **P < 0.01.
RESULTS
PATIENT CHARACTERISTIC
Clinical characteristics and symptom scores of all pa-
tients are summarized in Table 1. A significant higher
frequency of asthma was reported in CRSwNP pa-
tients, all other subjects were free of asthma symp-
toms. One-way anova showed that the total symptom
score was the highest in CRSwNP patients of which
nasal congestion and loss of smell were the most pre-
dominant symptoms. The scores for nasal congestion
and loss of smell were significantly higher in
CRSwNP vs CRSsNP patients, whereas CRSsNP pa-
tients reported higher symptom scores for headache
compared with the other disease groups. Finally,
CRSwNP showed the highest CT score compared
with CRSsNP.
HISTOPATHOLOGIC ANALYSIS
HE-stained sections are shown in Figure 1. CRSwNP
revealed a thickened basement membrane, a subepi-
thelial accumulation of eosinophils and edematous
change with pseudocyst formation (Fig. 1E, F). On
the other hand, in CRSsNP, fibrosis and accumula-
tion of not only eosinophils but also other inflamma-
tory cells (neutrophils, lymphocytes and so on) were
mostly found (Fig. 1C, D). The median (interquartile
range [IQR]) counts for eosinophils were signifi-
cantly higher in CRSwNP (15; 12-17) compared to
CRSsNP (6; 4-9; P = 0.02) and controls (1; 0-2; P <
0.001).
IMMUNOASSAY (ELISA)
The information on mediators, cytokines, and IgE in
tissue homogenates is shown in Figure 2. IL-5, total
IgE, SAE-IgE, and ECP levels in the tissue were sig-
nificantly and impressively increased in CRSwNP ver-
sus CTR and CRSsNP, whereas CRSsNP did not
demonstrate any significant change in the levels of
those proteins versus CTR. In clear contrast, TGF-β
protein level was significantly upregulated in CRSsNP
versus CTR and CRSwNP, whereas such upregula-
tion was not seen in CRSwNP. On the contrary, TGF-
β protein level was significantly downregulated in
CRSwNP versus not only CSRsNP but also CTR mu-
cosal samples. IL-1β protein level was significantly
upregulated in CRSsNP versus CTR and CRSwNP.
MPO and IL-8 levels in the tissue were significantly
increased in CRSsNP and CRSwNP versus CTR. IL-6
protein level was significantly increased in CRSsNP
versus CTR. The ECPMPO ratio is used to reflect
the observation that eosinophils and neutrophils are
present in polyps, and that the ratio between the two
allows to determine which cell type is more activated.
The ECPMPO ratio was significantly increased in
CRSwNP versus CRSsNP and CTR. IFN-γ and IL-17
protein data did not show any differences between
groups.
In 13 samples (68.4%) of CRSwNP, the ECPMPO
ratio was more than 1, and the same samples were IL-
5 positive, too. Besides, 10 samples (52.6%) of
CRSwNP were SAE-IgE positive, and 9 of these 10
samples were IL-5 positive, too. On the other hand, in
9 CRSsNP patients, only 2 samples were IL-5 positive,
and eosinophilic or SAE-IgE positive sample was only
one sample respectively.
In CRSwNP patients, 7 of 19 were atopic, whereas
only 2 of the 9 CRSsNP patients were atopic. In atopic
versus non-atopic CRSwNP, ECP, IL-5, IgE and SAE-
IgE levels were significantly increased (Table 2). On
the other hand, in CRSwNP patients, 6 of 19 were
asthmatic, and 5 of these 6 asthmatic patients were
both IL-5 and SAE-IgE positive. However, none of the
other group patients was asthmatic. In asthmatic ver-
sus non-asthmatic CRSwNP, ECP, total IgE, IL-8 and
MPO levels were significantly increased (Table 3).
In further examination of CRSwNP, 19 CRSwNP
patients could be classified in 2 groups; one was IL-5
positive group (n = 11), and the other was IL-5 nega-
tive group (n = 8).
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Table　3　 Cytokine concentrations in CRSwNP subgroups with and without asthma comorbidity
CRSwNP with asthma (n = 6) CRSwNP without asthma (n = 13) P value
ECP (μg/L) 13150 (4410-44750) 5750 (2250-16550) 0.041*
MPO (ng/mL) 18941 (1601-24683) 637 (273-3919) 0.024*
IL-5 (pg/mL) 32 (6-720) 37 (6-65) 0.788
IFN-γ (pg/mL) 78 (78-78) 156 (78-1016) 0.298
IgE (KU/L) 975 (477-1265) 354 (143-540) 0.009**
SAE-IgE (KU/L) 7.4 (0-8.2) 0 (0-5.3) 0.316
IL-1β (pg/mL) 977 (9-1067) 29 (23-128) 0.412
IL-6 (pg/mL) 351 (76-461) 95 (47-1109) 0.412
IL-8 (pg/mL) 53400 (25243-115829) 1550 (649-5345) 0.014*
IL-17 (pg/mL) 11 (11-141) 11 (11-11) 0.495
TGF-β (pg/mL) 18809 (4089-30338) 13542 (10102-13837) 0.230
Data are expressed as medians and interquartile ranges. *P < 0.05 and **P < 0.01.
DISCUSSION
Recent guidelines in western countries have at-
tempted to classify CRS subgroups and unify the cur-
rent pathophysiologic concepts.10,13 Although most of
the symptoms occur in both diseases, CRSwNP have
a more pronounced nasal obstruction and loss of
smell, while in CRSsNP patients complain more of
headache. Especially, the partial or complete loss of
smell with a concomitant effect on taste is a charac-
teristic feature of CRSwNP.14
In this study, we demonstrated clear differences in
the local tissue concentrations of mediators between
CRSsNP and CRSwNP. These differences are re-
flected by an inflammation pattern in the tissue of
CRSsNP and CRSwNP, respectively. Especially,
CRSwNP demonstrate increased IL-5 protein levels
compared with controls and CRSsNP. Additionally,
ECP as a marker of eosinophilic activation, and total
IgE as another Th2 stigma are significantly up-
regulated in CRSwNP versus controls and CRSsNP.
Besides, in CRSwNP, these cytokine and eosinophilic
mediators were increased in atopic patients versus
non-atopic patients.
In western countries, ECP has been described to
be significantly increased in CRSwNP vs controls and
CRSsNP,2,15 and here we show these phenomena also
found in Japanese samples. The ECPMPO ratio was
2.4 in CRSwNP but 0.5 in CRSsNP, evidencing an
eosinophil bias in CRSwNP versus a neutrophil bias
of inflammation in CRSsNP. The proinflammatory
mediator IL-1β and related cytokine IL-6 was signifi-
cantly increased in CRSsNP vs controls. We previ-
ously reported that the pattern of cytokines in
CRSwNP is remarkably different among the regions,
for examples, with a Th1Th17 dominance in South
Chinese polyps and a Th2 dominance in Belgian pol-
yps.7,8 The pattern of cytokines in our study is similar
to that in European CRSwNP. However, there has
been no study for cytokines or mediators in CRS
based on this classification in Japan. It was thought to
be the first study that showed the cytokine profiles in
Japanese CRSswNP similar to those of European
CRS.
TGF-β up-regulation is characteristic for CRSsNP,
whereas low TGF-β protein levels appear to be a con-
stant finding in CRSwNP, which could point to either
an increased T-regulatory cell activity16 or an in-
creased fibrogenic potential17,18 in CRSsNP. An over-
expression of TGF-β has been demonstrated before
in CRSsNP vs CRSwNP, confirming our current re-
sults.19 TGF-β is also a potent fibrogenic cytokine that
stimulates extracellular matrix formation, with in-
creased levels contributing to fibrosis in CRSsNP,
and a relative deficit in TGF-β explaining edema for-
mation in CRSwNP. In CRSsNP, we recently reported
that tissue inhibitor-1 (TIMP-1) is upregulated to-
gether with matrix metalloproteinases (MMP)-9,20
and high level of TGF-β121 and low activity of urok-
inase type plasminogen activator (u-PA)22 are ob-
served, so that fibrosis is considered to proceed in
the extracellular matrix. On the other hand, in
CRSwNP, TIMP-1 is not up-regulated, and high level
of MMP-7-9,20 high activity of u-PA22 and low level of
TGF-β121 are observed, so that fibrinolysis is consid-
ered to proceed in the extracellular matrix. TGF-β
down-regulates u-PA by activating PAI-1 which is in-
hibitor of u-PA, whereas u-PA convert pro-MMPs to
active MMPs via plasmin, and u-PA itself also acti-
vates MMPs.23
It is known that SAE acting as superantigens are
able to induce a polyclonal activation of T cells and
cause an exacerbation of the ongoing inflamma-
tion.24,25 Recent insights have linked the inflamma-
tion in CRSwNP to an increased prevalence of coloni-
zation with S. aureus and the release of their cell
products.26 SAE-IgE and consecutive polyclonal IgE
formation has been demonstrated in CRSwNP tissue,
which correlates with markers of eosinophilic inflam-
mation, pointing to a possible modifying role of bacte-
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rial superantigens in the pathophysiology of
CRSwNP.27,28 The presence of SAE-IgE also coin-
cided with higher levels of IL-5, eotaxin, and ECP.
The strikingly high correlation between IL-5 and IgE
antibody concentrations in CRSwNP homogenates
supports the hypothesis that SAE, apart from T cells,
also modify B and plasma cells.15 In contrast, SAE-
IgE and polyclonal IgE formation in tissue was a rare
finding in CRSsNP. Besides, we demonstrated that
the tissue from asthmatic or atopic patients with
CRSwNP showed SAE-IgE and Th2 mediators posi-
tive with the high rate in Table 2, 3. SAE-IgE is found
more frequently in NP versus controls and correlates
with higher levels of IL-5 and ECP.27 Moreover, an in-
creased number of T cells expressing the TCR b-
chain variable region, known to be induced by micro-
bial superantigens, was detected in NP and corre-
lated with the presence of SAE-IgE.29 These findings
confirm the role played by SAE as disease modifiers
specifically in asthma andor atopic disease with
CRSwNP. Because IL-5 is thought to be highly in-
volved in CRSwNP pathogenesis (Fig. 2), we chose it
as a marker, which divides CRSwNP into subgroups.
IL-5 positive CRSwNP group showed negative IL-17
and negative IFN-γ, and all asthmatic patients were in-
cluded in this group. IL-5 negative CRSwNP group
showed IL-17 positive, and it suggested that a certain
type of CRSwNP was modified by not IL-5 but IL-17.
To analyze the cytokine pattern may be important for
the management of CRSwNP and the risk for the de-
velopment of asthma.
An intense clinical phenotyping of patients with
chronic sinus disease with the measurement of in-
flammatory and T-cell markers could lead to the rec-
ognition of several sinus disease entities which will al-
low to finally introduce new definitions for studies on
the epidemiology, diagnostic management, and lower
airway co-morbidities, and eventually will open differ-
entiated and new therapeutic approaches. For exam-
ple, anti-IgE, anti-IL-5 or anti-IL-17 therapy may be
useful treatment for CRSwNP in the future.
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